Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018

Ju Yup Lee, Nayoung Kim, Ryoung Hee Nam, Soo In Choi, Jung Won Lee, Dong Ho Lee

Research output: Contribution to journalArticle

Abstract

Background: Antimicrobial resistance of Helicobacter pylori (H pylori) affects the efficacy of eradication therapy. The aim of this study was to estimate the prevalence of primary and secondary resistance of H pylori isolates to antibiotics in Korea. Methods: The present study was performed from 2003 to 2018. Primary resistance was evaluated in 591 patients without any history of eradication and secondary resistance in 149 patients from whom Helicobacter pylori was cultured after failure of eradication. A minimal inhibitory concentration test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin using the agar dilution method. Results: An increase in the primary resistance rate was found in clarithromycin (P <.001), metronidazole (P <.001), and both levofloxacin (P <.001) during the study period. The primary resistance rates of amoxicillin and tetracycline were low and stable during the study period. The secondary resistance rate significantly increased in metronidazole and levofloxacin (P =.022 and.039, respectively). Conclusions: The primary and secondary resistance rates of clarithromycin, metronidazole, and levofloxacin for Helicobacter pylori in Korea were high and increased over time. However, the primary and secondary resistance rates of amoxicillin and tetracycline were low and stable over time. These results will help in selecting effective eradication regimens of H pylori in Korea in the future.

Original languageEnglish
Article numbere12660
JournalHelicobacter
Volume24
Issue number6
DOIs
StatePublished - 1 Dec 2019

Fingerprint

Korea
Microbial Drug Resistance
Levofloxacin
Helicobacter pylori
Metronidazole
Clarithromycin
Amoxicillin
Tetracycline
Rifabutin
Agar
Anti-Bacterial Agents
Therapeutics

Keywords

  • Helicobacter pylori
  • antibiotics
  • prevalence
  • resistance

Cite this

Lee, Ju Yup ; Kim, Nayoung ; Nam, Ryoung Hee ; In Choi, Soo ; Lee, Jung Won ; Lee, Dong Ho. / Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. In: Helicobacter. 2019 ; Vol. 24, No. 6.
@article{64e5ba6c11834e13aa3b46a3b0e5d5ee,
title = "Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018",
abstract = "Background: Antimicrobial resistance of Helicobacter pylori (H pylori) affects the efficacy of eradication therapy. The aim of this study was to estimate the prevalence of primary and secondary resistance of H pylori isolates to antibiotics in Korea. Methods: The present study was performed from 2003 to 2018. Primary resistance was evaluated in 591 patients without any history of eradication and secondary resistance in 149 patients from whom Helicobacter pylori was cultured after failure of eradication. A minimal inhibitory concentration test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin using the agar dilution method. Results: An increase in the primary resistance rate was found in clarithromycin (P <.001), metronidazole (P <.001), and both levofloxacin (P <.001) during the study period. The primary resistance rates of amoxicillin and tetracycline were low and stable during the study period. The secondary resistance rate significantly increased in metronidazole and levofloxacin (P =.022 and.039, respectively). Conclusions: The primary and secondary resistance rates of clarithromycin, metronidazole, and levofloxacin for Helicobacter pylori in Korea were high and increased over time. However, the primary and secondary resistance rates of amoxicillin and tetracycline were low and stable over time. These results will help in selecting effective eradication regimens of H pylori in Korea in the future.",
keywords = "Helicobacter pylori, antibiotics, prevalence, resistance",
author = "Lee, {Ju Yup} and Nayoung Kim and Nam, {Ryoung Hee} and {In Choi}, Soo and Lee, {Jung Won} and Lee, {Dong Ho}",
year = "2019",
month = "12",
day = "1",
doi = "10.1111/hel.12660",
language = "English",
volume = "24",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. / Lee, Ju Yup; Kim, Nayoung; Nam, Ryoung Hee; In Choi, Soo; Lee, Jung Won; Lee, Dong Ho.

In: Helicobacter, Vol. 24, No. 6, e12660, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018

AU - Lee, Ju Yup

AU - Kim, Nayoung

AU - Nam, Ryoung Hee

AU - In Choi, Soo

AU - Lee, Jung Won

AU - Lee, Dong Ho

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Antimicrobial resistance of Helicobacter pylori (H pylori) affects the efficacy of eradication therapy. The aim of this study was to estimate the prevalence of primary and secondary resistance of H pylori isolates to antibiotics in Korea. Methods: The present study was performed from 2003 to 2018. Primary resistance was evaluated in 591 patients without any history of eradication and secondary resistance in 149 patients from whom Helicobacter pylori was cultured after failure of eradication. A minimal inhibitory concentration test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin using the agar dilution method. Results: An increase in the primary resistance rate was found in clarithromycin (P <.001), metronidazole (P <.001), and both levofloxacin (P <.001) during the study period. The primary resistance rates of amoxicillin and tetracycline were low and stable during the study period. The secondary resistance rate significantly increased in metronidazole and levofloxacin (P =.022 and.039, respectively). Conclusions: The primary and secondary resistance rates of clarithromycin, metronidazole, and levofloxacin for Helicobacter pylori in Korea were high and increased over time. However, the primary and secondary resistance rates of amoxicillin and tetracycline were low and stable over time. These results will help in selecting effective eradication regimens of H pylori in Korea in the future.

AB - Background: Antimicrobial resistance of Helicobacter pylori (H pylori) affects the efficacy of eradication therapy. The aim of this study was to estimate the prevalence of primary and secondary resistance of H pylori isolates to antibiotics in Korea. Methods: The present study was performed from 2003 to 2018. Primary resistance was evaluated in 591 patients without any history of eradication and secondary resistance in 149 patients from whom Helicobacter pylori was cultured after failure of eradication. A minimal inhibitory concentration test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin using the agar dilution method. Results: An increase in the primary resistance rate was found in clarithromycin (P <.001), metronidazole (P <.001), and both levofloxacin (P <.001) during the study period. The primary resistance rates of amoxicillin and tetracycline were low and stable during the study period. The secondary resistance rate significantly increased in metronidazole and levofloxacin (P =.022 and.039, respectively). Conclusions: The primary and secondary resistance rates of clarithromycin, metronidazole, and levofloxacin for Helicobacter pylori in Korea were high and increased over time. However, the primary and secondary resistance rates of amoxicillin and tetracycline were low and stable over time. These results will help in selecting effective eradication regimens of H pylori in Korea in the future.

KW - Helicobacter pylori

KW - antibiotics

KW - prevalence

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85072165736&partnerID=8YFLogxK

U2 - 10.1111/hel.12660

DO - 10.1111/hel.12660

M3 - Article

C2 - 31507036

AN - SCOPUS:85072165736

VL - 24

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 6

M1 - e12660

ER -